EE04047B1 - Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid - Google Patents

Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Info

Publication number
EE04047B1
EE04047B1 EE9700240A EE9700240A EE04047B1 EE 04047 B1 EE04047 B1 EE 04047B1 EE 9700240 A EE9700240 A EE 9700240A EE 9700240 A EE9700240 A EE 9700240A EE 04047 B1 EE04047 B1 EE 04047B1
Authority
EE
Estonia
Prior art keywords
ftc
zidovudine
synergistic combinations
synergistic
combinations
Prior art date
Application number
EE9700240A
Other languages
English (en)
Estonian (et)
Other versions
EE9700240A (et
Inventor
Walter Barry David
Heider St. Clair Martha
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04047(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700240A publication Critical patent/EE9700240A/xx
Publication of EE04047B1 publication Critical patent/EE04047B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
EE9700240A 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid EE04047B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
EE9700240A EE9700240A (et) 1998-04-15
EE04047B1 true EE04047B1 (et) 2003-06-16

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700240A EE04047B1 (et) 1995-03-30 1996-03-28 Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid

Country Status (35)

Country Link
US (1) US6417191B1 (https=)
EP (1) EP0817637B1 (https=)
JP (1) JP2954357B2 (https=)
KR (1) KR100542536B1 (https=)
CN (1) CN1103593C (https=)
AP (1) AP652A (https=)
AT (1) ATE220551T1 (https=)
AU (1) AU715213B2 (https=)
BR (3) BR9607851B1 (https=)
CA (1) CA2216634C (https=)
CZ (1) CZ295940B6 (https=)
DE (3) DE122005000029I2 (https=)
DK (1) DK0817637T3 (https=)
EA (1) EA000626B3 (https=)
EE (1) EE04047B1 (https=)
ES (1) ES2179193T3 (https=)
FR (1) FR05C0022I2 (https=)
GE (1) GEP20022647B (https=)
HU (1) HU224010B1 (https=)
IL (1) IL117727A (https=)
LU (1) LU91171I2 (https=)
MX (1) MX9707316A (https=)
MY (1) MY115461A (https=)
NL (1) NL300195I2 (https=)
NO (2) NO313787B1 (https=)
NZ (1) NZ306419A (https=)
OA (1) OA10616A (https=)
PL (1) PL187085B1 (https=)
PT (1) PT817637E (https=)
RO (1) RO117995B1 (https=)
SI (1) SI0817637T1 (https=)
SK (1) SK283825B6 (https=)
TR (1) TR199701074T1 (https=)
UA (1) UA60293C2 (https=)
WO (1) WO1996030025A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
AR012702A1 (es) * 1997-05-17 2000-11-08 Glaxo Group Ltd Combinacion de (-)-(1s,4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]- 2-ciclopenteno-1-metanol y un inhibidor dee transcriptasa reversa no nucleosidouna formulacion farmaceutica que comprende la combinacion, su uso medico en terapia para tratar la infeccion de vih, y un empaque para el paciente
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
TW200403061A (en) * 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
PL1692516T3 (pl) 2003-10-24 2011-05-31 Immunaid Pty Ltd Sposób terapii
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
PL2120878T3 (pl) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd Postać dawkowania zawierająca dwa czynne składniki farmaceutyczne o różnych postaciach fizycznych
PT2435825E (pt) 2009-05-27 2015-11-02 Biotempus Ltd Métodos para o tratamento de doenças
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
CA3077739A1 (en) * 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992020344A1 (en) 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
AU4079593A (en) * 1992-05-13 1993-12-13 Wellcome Foundation Limited, The Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
IL127350A0 (en) 1996-06-25 1999-10-28 Glaxo Group Ltd Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Also Published As

Publication number Publication date
PL187085B1 (pl) 2004-05-31
BR9607851B1 (pt) 2009-01-13
NO313787B1 (no) 2002-12-02
AP9701089A0 (en) 1997-10-31
GEP20022647B (en) 2002-03-25
UA60293C2 (uk) 2003-10-15
PL322532A1 (en) 1998-02-02
EP0817637B1 (en) 2002-07-17
DE122005000029I2 (de) 2006-04-27
DE122005000029I1 (de) 2005-10-06
MX9707316A (es) 1997-11-29
CN1185110A (zh) 1998-06-17
JPH10511682A (ja) 1998-11-10
HK1009401A1 (en) 1999-09-10
SI0817637T1 (en) 2002-10-31
BR9607851A (pt) 1998-07-21
NL300195I2 (nl) 2005-11-01
NO974510L (no) 1997-09-29
US6417191B1 (en) 2002-07-09
IL117727A (en) 1999-11-30
EA199700203A1 (ru) 1998-02-26
LU91171I9 (https=) 2018-12-28
HUP9801571A2 (hu) 1999-01-28
JP2954357B2 (ja) 1999-09-27
EE9700240A (et) 1998-04-15
CA2216634C (en) 2004-07-20
NO2005014I2 (no) 2008-02-11
NO2005014I1 (no) 2005-06-06
BRPI9612992B1 (pt) 2020-08-04
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
AU5497296A (en) 1996-10-16
RO117995B1 (ro) 2002-12-30
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
AP652A (en) 1998-06-19
NO974510D0 (no) 1997-09-29
ATE220551T1 (de) 2002-08-15
FR05C0022I1 (https=) 2005-06-10
DE69622386D1 (de) 2002-08-22
AU715213B2 (en) 2000-01-20
SK129597A3 (en) 1998-07-08
EP0817637A1 (en) 1998-01-14
EA000626B1 (ru) 1999-12-29
DE69622386T2 (de) 2003-02-13
HUP9801571A3 (en) 2001-04-28
OA10616A (en) 2001-03-15
CA2216634A1 (en) 1996-10-03
CZ295940B6 (cs) 2005-12-14
BRPI9607851B8 (pt) 2019-11-05
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
KR19980703420A (ko) 1998-11-05
CZ309097A3 (cs) 1998-05-13
EA000626B3 (ru) 2016-04-29
ES2179193T3 (es) 2003-01-16
MY115461A (en) 2003-06-30
DK0817637T3 (da) 2002-11-11
CN1103593C (zh) 2003-03-26
KR100542536B1 (ko) 2006-03-23
LU91171I2 (fr) 2005-07-04
FR05C0022I2 (https=) 2005-10-21
IL117727A0 (en) 1996-07-23
HU224010B1 (hu) 2005-04-28

Similar Documents

Publication Publication Date Title
EE04047B1 (et) Sidovudiini, 1592U89 ja 3TC või FTC sünergistlikud kombinatsioonid
EE03741B1 (et) N-propargüül-1-aminoindaani R-enantiomeeri, sellesoolade ja kompositsioonide kasutamine
BR9508677A (pt) Copolímero prodesso de preparação do mesmo e composição orgânica
EE03427B1 (et) Pihusti sõlm ja selle kasutamine
DK0832104T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
FI964311L (fi) Bifunktionaalinen proteiini, valmistus ja käyttö
FI20105336L (fi) Sinkkisormiproteiinijohdannaisia ja niiden menetelmiä
FI960889A7 (fi) Naftyyliyhdisteitä, välituotteita, koostumuksia ja menetelmiä
FI952158L (fi) Hiihtokäsine ja hihtosauva sekä niiden yhdistelmä
NO961721D0 (no) 2-oksetanon-limingsmidler, deres fremstilling og bruk
NO986034D0 (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
DE69634489D1 (de) Adenovirus dodekahedrischer proteinkomplex, dieser enthaltende zusammensetzung und verwendungen davon
DK0840548T3 (da) Synergistisk, herbicid sammensætning samt fremgangsmåde til fremstilling deraf
FI972988A0 (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
DK60893D0 (da) Piperidinderivater, deres fremstilling og anvendelse
EE9800451A (et) Uued imidasotriasolopürimidiinid, nende valmistamismeetod ja kasutamine ravimainetena
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
PT826679E (pt) Compostos de naftilo intermediarios composicoes e metodos de utilizacao
BR9610382A (pt) Composição de tratamento do cableo
FI972965A7 (fi) Uusia peptidejä, niiden valmistus ja käyttö
EE200000018A (et) 6-pürrolidiin-2-üülpüridiinid, nende valmistamine ja terapeutiline kasutamine
FI971872L (fi) Proteiinikoostumus ja sen valmistus ja käyttö sekä sitä sisältävät valmisteet ja näiden valmistus
NO972821D0 (no) 1-C-perfluoralkylglycosider, deres fremstilling og anvendelse
FI964446L (fi) Uusia tetrapeptidejä, niiden valmistus ja käyttö
FI942331L (fi) Biosidisia koostumuksia ja niiden käyttö

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

FG1Y Spc granted

Free format text: PRODUCT NAME: KIVEXA; NAT. REGISTRATION NO/DATE: C(2004)5373 20041217; FIRST REGISTRATION: EU/1/04/298/001-002

Spc suppl protection certif: C20050002 00007

Filing date: 20050512

Extension date: 20191217

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

SPCM Correction and amendment to the data concerning application for a supplementary protection certificate

Spc suppl protection certif: C20050002 00007

Extension date: 20191222

SPCX Term of validity of supplementary protection expired

Spc suppl protection certif: 00007

Extension date: 20211209